Live Analyst Rating Changes 36699 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Les Sulewski
OPCO

Les Sulewski

Oppenheimer
Wall Street Analyst
★★★★☆
#394
on 13Foresight · ranked by our own returns
71%
Success Rate
+7.2%
Average Return
15 of 21 calls profitable · +71.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 71% of Les Sulewski's ratings turned a profit when each position was held for 2 year — averaging +7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

59 Buy 10 Hold 0 Sell
Les's Stock Coverage 15 ratings · 2026-10-04
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
FR:MEDCL
MedinCell SA
 Sep 23, 2026 BUY Strong Buy
+55.6% avg upside
3 analysts
$35.00
57.70% Upside
 -5.5% ·
INVA
Innoviva
 Sep 23, 2026 BUY Buy
+42.9% avg upside
13 analysts
$35.00
70.76% Upside
 +4.8% ·
VNDA
Vanda
 Sep 23, 2026 BUY Strong Buy
+318.4% avg upside
13 analysts
$10.00
116.00% Upside
 -8.1% ·
ANIP
ANI Pharmaceuticals
 Sep 23, 2026 HOLD Strong Buy
+39.6% avg upside
12 analysts
$85.00
17.83% Upside
 +0.5% ·
COLL
Collegium Pharmaceutical
 Sep 23, 2026 BUY Strong Buy
+90.0% avg upside
10 analysts
$50.00
127.06% Upside
 +0.4% ·
AMRX
Amneal Pharmaceuticals
 Sep 23, 2026 BUY Strong Buy
-6.1% avg upside
19 analysts
$27.00
32.97% Upside
 +3.8% ·
IL:TEVA
Teva
 Sep 23, 2026 BUY Strong Buy
+17.7% avg upside
7 analysts
$15261.63
25.46% Upside
 · ·
VTRS
Viatris
 Sep 23, 2026 BUY Buy
+33.2% avg upside
22 analysts
$25.00
42.06% Upside
 +2.8% ·
PCRX
Pacira Pharmaceuticals
 Sep 23, 2026 BUY Buy
+50.5% avg upside
22 analysts
$32.00
26.97% Upside
 +2.4% ·
CRMD
Cormedix
 May 15, 2026 BUY Strong Buy
+109.2% avg upside
13 analysts
 — +2.0% ·
TSE:BHC
Bausch Health Companies
 May 01, 2026 HOLD Buy
+616.9% avg upside
29 analysts
 — +7.8% ·
BTMD
biote
 Apr 16, 2026 BUY Strong Buy
+290.1% avg upside
8 analysts
$4.00
247.88% Upside
 -42.4% ·
CVS
CVS Health
 Aug 08, 2024 BUY Strong Buy
+24.4% avg upside
39 analysts
 — +78.5% ·
TSE:DHT.UN
DRI Healthcare
 Jul 26, 2024 BUY Strong Buy
+18.2% avg upside
8 analysts
$19.95
8.49% Upside
 +56.9% ·
XAIR
Beyond Air
 Jul 09, 2024 HOLD Strong Buy
+2985.9% avg upside
11 analysts
 — · ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Les Sulewski — Frequently Asked Questions
How accurate are Les Sulewski's stock ratings?
Based on the calls 13Foresight could measure, about 71% of Les's ratings were profitable over a one-year hold, with an average return of +4.5% per rating, or -1.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Les ranked on 13Foresight?
Les Sulewski is currently ranked #394 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Les cover?
Les most recently has ratings on FR:MEDCL, INVA, VNDA, ANIP, COLL, AMRX, IL:TEVA, VTRS, PCRX, CRMD, TSE:BHC, BTMD and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.